1. Home
  2. OMH vs SCYX Comparison

OMH vs SCYX Comparison

Compare OMH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMH
  • SCYX
  • Stock Information
  • Founded
  • OMH 2015
  • SCYX 1999
  • Country
  • OMH Singapore
  • SCYX United States
  • Employees
  • OMH N/A
  • SCYX N/A
  • Industry
  • OMH Real Estate
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • OMH Finance
  • SCYX Health Care
  • Exchange
  • OMH Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • OMH 35.8M
  • SCYX 34.9M
  • IPO Year
  • OMH 2023
  • SCYX 2014
  • Fundamental
  • Price
  • OMH $1.20
  • SCYX $1.12
  • Analyst Decision
  • OMH Hold
  • SCYX
  • Analyst Count
  • OMH 1
  • SCYX 0
  • Target Price
  • OMH N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • OMH 213.6K
  • SCYX 195.8K
  • Earning Date
  • OMH 09-25-2025
  • SCYX 11-05-2025
  • Dividend Yield
  • OMH N/A
  • SCYX N/A
  • EPS Growth
  • OMH N/A
  • SCYX N/A
  • EPS
  • OMH N/A
  • SCYX N/A
  • Revenue
  • OMH $7,976,578.00
  • SCYX $3,257,000.00
  • Revenue This Year
  • OMH $28.40
  • SCYX $422.61
  • Revenue Next Year
  • OMH $23.07
  • SCYX $240.56
  • P/E Ratio
  • OMH N/A
  • SCYX N/A
  • Revenue Growth
  • OMH 117.53
  • SCYX N/A
  • 52 Week Low
  • OMH $0.59
  • SCYX $0.66
  • 52 Week High
  • OMH $5.46
  • SCYX $1.66
  • Technical
  • Relative Strength Index (RSI)
  • OMH 49.17
  • SCYX 74.20
  • Support Level
  • OMH $1.08
  • SCYX $0.81
  • Resistance Level
  • OMH $1.60
  • SCYX $0.88
  • Average True Range (ATR)
  • OMH 0.11
  • SCYX 0.07
  • MACD
  • OMH 0.02
  • SCYX 0.03
  • Stochastic Oscillator
  • OMH 26.36
  • SCYX 62.33

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: